9 news items
12 Health Care Stocks Moving In Friday's After-Market Session
ACRS
ADIL
BCLI
24 May 24
session. The market value of their outstanding shares is at $49.0 million.
Innovative Eyewear
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BCLI
20 May 24
Reinventing the Surrogate Landscape: Innovating Regulatory Acceptable Endpoints Most Meaningful to People Living with ALS
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
BCLI
14 May 24
and development, with a proven track record of leading successful clinical trials and fostering innovation in drug development. In addition, after four
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BCLI
16 Apr 24
trials and fostering innovation in drug development. Prior to joining Brainstorm he was Chief Medical Officer at Enveric Biosciences where he
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
BCLI
11 Apr 24
.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative
qocutq3gli6yzrx1rj2zkyyj9l1c6j5h27wz8lkqt32kn3jl6xi1
BCLI
10 Apr 24
disorders. MSC-NTF cells are harvested from each person with ALS and are manufactured using an innovative and proprietary process, to secrete neurotrophic
u4zzau9u87o loddwgcx6bvslffcnpezfxy5o8gt22quslvdu1ljzzexwrqc
BCLI
9 Apr 24
. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem
g0lzniorbd 5mlmpbh7cz07qnuu23lexjv
BCLI
8 Apr 24
BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative
ioqg7e1zd bigiinv6r2if
BCLI
1 Apr 24
Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases
- Prev
- 1
- Next